New topical microemulsions of etofenamate as sufficient management of osteoarthritis
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Brazilian Journal of Pharmaceutical Sciences |
Texto Completo: | https://www.revistas.usp.br/bjps/article/view/205308 |
Resumo: | In this study, microemulsions containing etofenamate were prepared and evaluated as dermal delivery carriers. The developed microemulsions consist of oleic acid, Span 80, Tween 20, Cremophor EL, Transcutol and ethanol. The percentage of etofenamate loading in the microemulsions was 5% (w/w). The characterization of formulations included droplet size, zeta potential, pH, conductivity, PDI, refractive index and viscosity. Moreover, ex vivo penetration study was carried out using mice abdominal skin. The developed formulations were analyzed for their cytotoxicity via MTT assay and tested for their anti-inflammatory properties opposed to LPS-stimulated nitrite prοduction in RAW 264.7 cells. As ideal formulation, M2ETF, was chosen due to its greater permeation, lower penetration as well as higher anti-inflammatory activity compared to other microemulsions. |
id |
USP-31_477350bc308c4c887719c8cf71e7a87b |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/205308 |
network_acronym_str |
USP-31 |
network_name_str |
Brazilian Journal of Pharmaceutical Sciences |
repository_id_str |
|
spelling |
New topical microemulsions of etofenamate as sufficient management of osteoarthritisEtofenamateNonsteroidal anti-inflammatory drugMicroemulsionEx vivoCytotoxicityAnti-inflammatory activityIn this study, microemulsions containing etofenamate were prepared and evaluated as dermal delivery carriers. The developed microemulsions consist of oleic acid, Span 80, Tween 20, Cremophor EL, Transcutol and ethanol. The percentage of etofenamate loading in the microemulsions was 5% (w/w). The characterization of formulations included droplet size, zeta potential, pH, conductivity, PDI, refractive index and viscosity. Moreover, ex vivo penetration study was carried out using mice abdominal skin. The developed formulations were analyzed for their cytotoxicity via MTT assay and tested for their anti-inflammatory properties opposed to LPS-stimulated nitrite prοduction in RAW 264.7 cells. As ideal formulation, M2ETF, was chosen due to its greater permeation, lower penetration as well as higher anti-inflammatory activity compared to other microemulsions.Universidade de São Paulo. Faculdade de Ciências Farmacêuticas2022-12-23info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/bjps/article/view/20530810.1590/s2175-97902022e20123Brazilian Journal of Pharmaceutical Sciences; Vol. 58 (2022)Brazilian Journal of Pharmaceutical Sciences; v. 58 (2022)Brazilian Journal of Pharmaceutical Sciences; Vol. 58 (2022)2175-97901984-8250reponame:Brazilian Journal of Pharmaceutical Sciencesinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/bjps/article/view/205308/194914Copyright (c) 2022 Brazilian Journal of Pharmaceutical Scienceshttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessÜstündağ Okur, NeslihanOnay, EcehanKadıoğlu Yaman, BerilSipahi, Hande2023-06-07T14:02:16Zoai:revistas.usp.br:article/205308Revistahttps://www.revistas.usp.br/bjps/indexPUBhttps://old.scielo.br/oai/scielo-oai.phpbjps@usp.br||elizabeth.igne@gmail.com2175-97901984-8250opendoar:2023-06-07T14:02:16Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
New topical microemulsions of etofenamate as sufficient management of osteoarthritis |
title |
New topical microemulsions of etofenamate as sufficient management of osteoarthritis |
spellingShingle |
New topical microemulsions of etofenamate as sufficient management of osteoarthritis Üstündağ Okur, Neslihan Etofenamate Nonsteroidal anti-inflammatory drug Microemulsion Ex vivo Cytotoxicity Anti-inflammatory activity |
title_short |
New topical microemulsions of etofenamate as sufficient management of osteoarthritis |
title_full |
New topical microemulsions of etofenamate as sufficient management of osteoarthritis |
title_fullStr |
New topical microemulsions of etofenamate as sufficient management of osteoarthritis |
title_full_unstemmed |
New topical microemulsions of etofenamate as sufficient management of osteoarthritis |
title_sort |
New topical microemulsions of etofenamate as sufficient management of osteoarthritis |
author |
Üstündağ Okur, Neslihan |
author_facet |
Üstündağ Okur, Neslihan Onay, Ecehan Kadıoğlu Yaman, Beril Sipahi, Hande |
author_role |
author |
author2 |
Onay, Ecehan Kadıoğlu Yaman, Beril Sipahi, Hande |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Üstündağ Okur, Neslihan Onay, Ecehan Kadıoğlu Yaman, Beril Sipahi, Hande |
dc.subject.por.fl_str_mv |
Etofenamate Nonsteroidal anti-inflammatory drug Microemulsion Ex vivo Cytotoxicity Anti-inflammatory activity |
topic |
Etofenamate Nonsteroidal anti-inflammatory drug Microemulsion Ex vivo Cytotoxicity Anti-inflammatory activity |
description |
In this study, microemulsions containing etofenamate were prepared and evaluated as dermal delivery carriers. The developed microemulsions consist of oleic acid, Span 80, Tween 20, Cremophor EL, Transcutol and ethanol. The percentage of etofenamate loading in the microemulsions was 5% (w/w). The characterization of formulations included droplet size, zeta potential, pH, conductivity, PDI, refractive index and viscosity. Moreover, ex vivo penetration study was carried out using mice abdominal skin. The developed formulations were analyzed for their cytotoxicity via MTT assay and tested for their anti-inflammatory properties opposed to LPS-stimulated nitrite prοduction in RAW 264.7 cells. As ideal formulation, M2ETF, was chosen due to its greater permeation, lower penetration as well as higher anti-inflammatory activity compared to other microemulsions. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-12-23 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/bjps/article/view/205308 10.1590/s2175-97902022e20123 |
url |
https://www.revistas.usp.br/bjps/article/view/205308 |
identifier_str_mv |
10.1590/s2175-97902022e20123 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/bjps/article/view/205308/194914 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas |
publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas |
dc.source.none.fl_str_mv |
Brazilian Journal of Pharmaceutical Sciences; Vol. 58 (2022) Brazilian Journal of Pharmaceutical Sciences; v. 58 (2022) Brazilian Journal of Pharmaceutical Sciences; Vol. 58 (2022) 2175-9790 1984-8250 reponame:Brazilian Journal of Pharmaceutical Sciences instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Brazilian Journal of Pharmaceutical Sciences |
collection |
Brazilian Journal of Pharmaceutical Sciences |
repository.name.fl_str_mv |
Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
bjps@usp.br||elizabeth.igne@gmail.com |
_version_ |
1800222916591222784 |